7,577.96

+36.56

+0.48%

51,761.66

-222.32

-0.43%

25,409.61

+245.24

+0.97%

2,826.07

+20.19

+0.72%

4.9580

+0.0640

+1.31%

20.77

-0.38

-1.80%

3,937.70

-31.90

-0.80%

77,603.22

+574.85

+0.75%

Crude Oil Dec 26

95.99

-0.47

-0.49%

US Private Equity

10,836.30

-14.33

-0.13%

OTC Markets OTCPK - Delayed Quote USD

Genmab A/S (GNMSF)

574.50 +19.20 (+3.46%)

As of October 30 at 4:00:00 PM EDT. Market Open.

Loading Chart for GNMSF

Chart Range Bar

Interval:

In partnership with ChartIQ

Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus

Genmab Stock Price Shock Puts 3 Oncology Biotech Names In Focus

Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?

Can Genmab (CPSE:GMAB) Still Be Undervalued After Its Trial Wins?

Genmab’s bispecific halves risk of death in first-line HNSCC

Genmab soars to record highs after cancer drug succeeds in key trial

Genmab soars to record highs after cancer drug succeeds in key trial

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?

Why Did ETSY, REPL, GMAB Stocks Surge To 52-Week Highs Today?

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab’s Three Positive Phase III Readouts Set Stage for Potential 2027 Cancer Launches

Genmab Stock Surges to Record High After Stunning Cancer Drug Results

Genmab Stock Surges to Record High After Stunning Cancer Drug Results

Genmab Stock Hits 52-Week High - Here's Why

Genmab Stock Hits 52-Week High - Here's Why

Top Midday Gainers

Top Midday Gainers

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

GMAB Stock Hits All-Time High After Genmab’s Cancer Drug Trial Meets Primary Goals — Here’s What Investors Need To Know

Genmab stock surges 16% on positive cancer trial results

Genmab stock surges 16% on positive cancer trial results

Mobilize your Website

View Site in Mobile | Classic

Share by: